BridgeBio Oncology Therapeutics, Inc. (BBOT) Stock Forecast & Price Target
BridgeBio Oncology Therapeutics, Inc. · NASDAQ
$8.77-0.05 (-0.57%)
15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 9 firms covering BridgeBio Oncology Therapeutics, Inc, 9 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $20.00 to $29.00, a moderate spread. The average target of $24.22 sits 176% above the current $8.77. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 7 to 9 over recent months. On the fundamentals, the Street sees revenue growth near 0% this year and 0% next, consensus EPS building from about $-0.56 next quarter toward $-2.11 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS9 ratings
Moderate Buy
Strong Buy00%
Buy9100%
Hold00%
Sell00%
Strong Sell00%
Based on 9 analysts giving stock ratings to BridgeBio Oncology Therapeutics, Inc.
As of Jul, 9 of 9 firms rate BBOT a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
BBOT EPS & revenue forecast
EPS · NEXT QUARTER
$-0.56
Range $-0.71 – $-0.43 · 9 analysts · -46% YoY
Next period, 9 analysts expect BridgeBio Oncology Therapeutics, Inc. to earn $-0.56 a share (range $-0.71 – $-0.43), versus $-1.03 a year earlier. Full-year consensus is $-2.21, growing to $-2.11 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 9 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering BridgeBio Oncology Therapeutics, Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BBOT.
#1
David Nierengarten
Wedbush · Rank #115
Buy
$25.00+185.1% to target
Overall win rate
41%
+ Follow
#2
Andrew Berens
Leerink Partners · Rank #167
Buy
$41.00+367.5% to target
Overall win rate
50%
+ Follow
#3
RB
Robert Burns
HC Wainwright & Co. · Rank #195
Buy
$29.00+230.7% to target
Overall win rate
38%
+ Follow
#4
John Newman
Canaccord Genuity · Rank #340
Buy
$23.00+162.3% to target
Overall win rate
30%
+ Follow
#5
Matthew Biegler
Oppenheimer
Buy
$22.00+150.9% to target
Coverage
—
+ Follow
BBOT stock forecast FAQ
What is BBOT's average 12-month price target?+
The 9 analysts with a live target average $24.22 for BridgeBio Oncology Therapeutics, Inc. over the next 12 months, ranging from a $29.00 high to a $20.00 low.
Is BBOT stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 9 analyst ratings, 9 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for BBOT?+
The Street-high target is $29.00 (HC Wainwright & Co.), and the Street-low is $20.00 (Morgan Stanley). The average of all 9 active targets is $24.22.
How many Wall Street analysts cover BBOT?+
9 analysts have an active rating on BridgeBio Oncology Therapeutics, Inc., and 9 firms carry a live 12-month price target.
Who is the most accurate analyst covering BBOT?+
Among analysts who currently cover BBOT, David Nierengarten of Wedbush has the strongest overall Quantellect track record (Rank #115). Their current call is Buy with a $25.00 target.
What is BridgeBio Oncology Therapeutics, Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.56 per share (range $-0.71 – $-0.43) across 9 analysts. Full-year EPS is projected at $-2.21, rising to $-2.11 the following year.
How much revenue is BridgeBio Oncology Therapeutics, Inc. expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading BBOT lately?+
As of Jul, 9 of 9 firms rate BBOT a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BBOT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
Oppenheimer
